[go: up one dir, main page]

MX380758B - Compuesto que tiene actividad inhibitoria de idh mutante, método de preparación y usos del mismo. - Google Patents

Compuesto que tiene actividad inhibitoria de idh mutante, método de preparación y usos del mismo.

Info

Publication number
MX380758B
MX380758B MX2018011592A MX2018011592A MX380758B MX 380758 B MX380758 B MX 380758B MX 2018011592 A MX2018011592 A MX 2018011592A MX 2018011592 A MX2018011592 A MX 2018011592A MX 380758 B MX380758 B MX 380758B
Authority
MX
Mexico
Prior art keywords
compound
preparation
inhibitory activity
hdi
mutant
Prior art date
Application number
MX2018011592A
Other languages
English (en)
Other versions
MX2018011592A (es
Inventor
Feifei Liu
Huixin Wan
Jian Ding
Jianhua Cao
Lei Jiang
Meiyu Geng
Min Huang
Qiangang Zheng
Shuai Tang
Xianlei Fu
Xiaojing Lan
Original Assignee
Shanghai Haihe Pharmaceutical Co Ltd
Shanghai Inst Of Materia Medica Chinese Academy Of Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Haihe Pharmaceutical Co Ltd, Shanghai Inst Of Materia Medica Chinese Academy Of Sciences filed Critical Shanghai Haihe Pharmaceutical Co Ltd
Publication of MX2018011592A publication Critical patent/MX2018011592A/es
Publication of MX380758B publication Critical patent/MX380758B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Una proteína tolerante a herbicidas SUM1, su gen de codificación y un uso de la misma, en donde la proteína tolerante a herbicidas comprende: (a) una proteína que tiene una secuencia de aminoácidos tal como se muestra en SEC ID NO: 1; o (b) una proteína que se deriva de (a) sustituir y/o eliminar y/o agregar uno o más aminoácidos en la secuencia de aminoácidos de (a), y tiene la actividad de tifensulfuron hidrolasa. La proteína tolerante a herbicidas SUM1 puede mostrar una mayor tolerancia a una pluralidad de los herbicidas de sulfonilurea, puede tolerar una concentración de campo de cuatro veces y por ende tiene una amplia perspectiva de aplicación en las plantas.
MX2018011592A 2016-03-22 2017-03-21 Compuesto que tiene actividad inhibitoria de idh mutante, método de preparación y usos del mismo. MX380758B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610165095.1A CN107216312B (zh) 2016-03-22 2016-03-22 一种具有突变型idh抑制活性的化合物、其制备方法及用途
PCT/CN2017/077467 WO2017162133A1 (zh) 2016-03-22 2017-03-21 一种具有突变型idh抑制活性的化合物、其制备方法及用途

Publications (2)

Publication Number Publication Date
MX2018011592A MX2018011592A (es) 2019-06-24
MX380758B true MX380758B (es) 2025-03-12

Family

ID=59899244

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018011592A MX380758B (es) 2016-03-22 2017-03-21 Compuesto que tiene actividad inhibitoria de idh mutante, método de preparación y usos del mismo.

Country Status (11)

Country Link
US (1) US10682352B2 (es)
EP (1) EP3434674B1 (es)
JP (1) JP6718553B2 (es)
KR (1) KR102245434B1 (es)
CN (1) CN107216312B (es)
AU (1) AU2017239295B2 (es)
CA (1) CA3018602C (es)
EA (1) EA037974B1 (es)
ES (1) ES2870910T3 (es)
MX (1) MX380758B (es)
WO (1) WO2017162133A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110407855A (zh) * 2018-04-26 2019-11-05 上海嗣新生物科技有限公司 2-氨基嘧啶啶衍生物及其制备方法和用途
GB201814151D0 (en) 2018-08-31 2018-10-17 Ucl Business Plc Compounds
CN111825666B (zh) * 2019-04-23 2024-03-08 上海仕谱生物科技有限公司 二聚或多聚体形式的突变型idh抑制剂
CN112375069B (zh) * 2020-11-20 2022-09-13 湖北民族大学 一种4-脲基嘧啶类化合物及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2012005299A1 (ja) * 2010-07-07 2013-09-05 日本新薬株式会社 Ｒｏｓチロシンキナーゼ阻害剤
WO2012020786A1 (ja) * 2010-08-11 2012-02-16 日本新薬株式会社 医薬組成物
WO2012020787A1 (ja) * 2010-08-11 2012-02-16 日本新薬株式会社 悪性リンパ腫治療剤
SG11201400989TA (en) * 2011-09-27 2014-04-28 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
CA2903176A1 (en) 2013-03-14 2014-09-18 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
MX355945B (es) 2013-03-14 2018-05-07 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante.
WO2014147586A1 (en) * 2013-03-22 2014-09-25 Novartis Ag 1-(2-(ethylamino)pyrimidin-4-yl)pyrrolidin-2-ones as inhibitors of mutant idh
JP6648116B2 (ja) * 2014-09-19 2020-02-14 フォーマ セラピューティクス，インコーポレイテッド 変異イソクエン酸デヒドロゲナーゼ阻害剤としてのキノリノンピリミジン組成物

Also Published As

Publication number Publication date
US20190111056A1 (en) 2019-04-18
KR20180132721A (ko) 2018-12-12
CN107216312A (zh) 2017-09-29
EA201892098A1 (ru) 2019-07-31
KR102245434B1 (ko) 2021-04-29
JP6718553B2 (ja) 2020-07-08
EP3434674A1 (en) 2019-01-30
EP3434674A4 (en) 2019-11-27
MX2018011592A (es) 2019-06-24
CA3018602A1 (en) 2017-09-28
AU2017239295B2 (en) 2020-01-02
EA037974B1 (ru) 2021-06-18
WO2017162133A1 (zh) 2017-09-28
CN107216312B (zh) 2023-08-01
EP3434674B1 (en) 2021-02-24
ES2870910T3 (es) 2021-10-28
AU2017239295A1 (en) 2018-10-18
JP2019510819A (ja) 2019-04-18
CA3018602C (en) 2021-06-22
US10682352B2 (en) 2020-06-16

Similar Documents

Publication Publication Date Title
PH12020500265A1 (en) Indole carboxamides compounds useful as kinase inhibitors
PH12019500521A1 (en) Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
MX2021007432A (es) Compuestos y composiciones para inhibir la actividad de shp2.
PH12016501394A1 (en) Compounds for treating patients with ros1 mutant cancer cells
BR112018008966A2 (pt) compostos inibidores de jak quinase para o tratamento de doença respiratória
MX2020012165A (es) Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cancer.
ZA201606320B (en) Human plasma kallikrein inhibitors
MD4800B1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
TN2017000158A1 (en) Carbazole derivatives
MX2021010041A (es) Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt.
MX2021010297A (es) Inhibidores de calicreina plasmatica humana.
WO2016004413A3 (en) Gls1 inhibitors for treating disease
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
MX380758B (es) Compuesto que tiene actividad inhibitoria de idh mutante, método de preparación y usos del mismo.
MX2022007315A (es) Formulaciones de olanzapina de liberacion sostenida.
MX375329B (es) 2,2,2-trifluoroetil-tiadiazinas.
MX2019014773A (es) Inhibidores de ccl2.
NZ780408A (en) Human plasma kallikrein inhibitors